EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy

Wei-Hsin Liu, Anat Globerson Levin, Assaf Lask, Galit Horn, Tova Waks, Bar Nathansohn Levi, Irit Milman Krentsis, Einav Shoshan, Xiaohua Su, Maksim Mamonkin, Richard E Champlin, Yair Reisner iD und 1 weitere

Stem Cells Translational Medicine · 2025

DOI: 10.1093/stcltm/szaf020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2025. Verfasst von Wei-Hsin Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive, Immunologic Memory, Memory T Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cell Source Inc, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central memory CD8 T cells exhibit marked veto activity enhancing engraftment in several mouse models of T cell-depleted bone marrow (TDBM) allografting. Graft-versus-host disease (GVHD) can be prevented by stimulation of mouse or human memory CD8 T cells against their cognate antigens under cytokine deprivation, in the early phase of culture followed by further expansion with IL21, IL15, and IL7. Thus, human anti-viral CD8 central memory veto T cells generated from CMV and EBV-positive donors are currently evaluated in a clinical trial at MD Anderson Cancer Centre (MDACC). Results in 15 patients indicate a low risk of GVHD. Considering that these cells could offer an attractive platform for CAR cell therapy, we evaluated methodologies for their effective transduction with 2 retroviral vectors. Initially, a vector directed against Her2 was tested and optimal transduction was attained at day 5 of culture. The transduced cells were expanded for an additional 7 days and exhibited marked anti-tumor reactivity ex-vivo while retaining their veto activity. Transduction with a vector directed at CD19 was effectively attained at days 4-5 allowing for substantial harvest of transduced cells at day 12 of culture. These Veto-CD19CAR central memory CD8 T cells exhibited marked anti-tumor reactivity in-vitro and in-vivo without GVHD, measured following transplantation into immune-deficient mice. These results strongly suggest that Veto-CAR T cells offer an attractive platform for CAR T cell therapy without gene editing for addressing the risk of GVHD or graft rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesImmunotherapy, AdoptiveImmunologic MemoryMemory T CellsReceptors, Chimeric AntigenHumansAnimalsMiceGraft vs Host DiseaseFemale

Stichwörter der Autor:innen

adult hematopoietic stem cellscellular therapychimericclinical translationimmunotherapytransductiontransplantationtransplantation tolerance

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • University of Texas MD Anderson UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030, United States.
  • Immunology and advanced CAR-T cell therapy laboratory, Research & Development Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
  • Dotan Center for Advanced Therapies, Tel-Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv 6423906, Israel.
  • Department of Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX,77030, United States.

ORCID-Profile: Yair Reisner

Förderung

  • Cell Source Inc
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Liu, W. H., Globerson Levin, A., Lask, A., Horn, G., Waks, T., Nathansohn Levi, B., Milman Krentsis, I., Shoshan, E., Su, X., Mamonkin, M., Champlin, R. E., Reisner, Y., & Bachar Lustig, E. (2025). Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szaf020

Vancouver

Liu WH, Globerson Levin A, Lask A, Horn G, Waks T, Nathansohn Levi B, et al. Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy. Stem Cells Translational Medicine. 2025. doi:10.1093/stcltm/szaf020

BibTeX
@article{Liu2025,
  author = {Liu, Wei-Hsin and Globerson Levin, Anat and Lask, Assaf and Horn, Galit and Waks, Tova and Nathansohn Levi, Bar and Milman Krentsis, Irit and Shoshan, Einav and Su, Xiaohua and Mamonkin, Maksim and Champlin, Richard E and Reisner, Yair and Bachar Lustig, Esther},
  title = {Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy},
  journal = {Stem Cells Translational Medicine},
  year = {2025},
  doi = {10.1093/stcltm/szaf020}
}
Kostenlos starten →